Highlighted Prostate Cancer Trials and Studies

As part of Us TOO’s continued commitment to bring news of new interventions and treatments for the benefit of prostate cancer patients, we are pleased to share this news with you about the following opportunities to participate in clinical trials.

Prostate Cancer Research Studies in Chicago Area

Organ confined/localized

Locally advanced

Rising PSA post-initial treatment

Hormone refractory/hormone resistant

Hormone refractory/hormone resistant AND Metastatic

Psycho/social

Multiple trials

TRIAL DESCRIPTIONS

Prostate Cancer Research Studies in Chicago Area

  • Penile Rehabilitation

    If you or someone you knows in the Chicago area had treatment for prostate cancer with surgery or radiation in the past 3 months and is interested in working on penile rehabilitation to preserve pre-treatment erectile function and you may also be eligible to participate in a research study using questionnaires to examine quality of life after prostate cancer treatment. To learn more about the penile rehabilitation program call 847-503-4245.

  • The Lived Experience of Men with Sexual Dysfunction after Prostate Cancer Treatment

    Researchers at NorthShore University HealthSystem want to learn how erectile dysfunction after prostate cancer treatment impacts quality of life of men and their partners. Participants complete a one-time interview with the study investigator or member of the research staff. Cancer survivors will also complete a one-time questionnaire about their symptoms and problems. If you are a man or partner of a man in the Chicago area who has undergone radical prostatectomy (surgery) or radiation therapy for prostate cancer at least 1 year ago and no more than 5 years ago you may be able to participate in the study. Call 847-503-4281 for more information. As part of Us TOO’s continued commitment to bring news of new interventions and treatments for the benefit of prostate cancer patients, we are pleased to share this news with you about the following opportunities to participate in clinical trials.

Organ confined/localized

  • The ATLAS Study - A clinical research study now enrolling for men who have high-risk, localized or locally advanced prostate cancer and are receiving radiation therapy (Enrollment deadline: April 2019)

    The ATLAS Study is a clinical research study now enrolling for men who have high-risk, localized or locally advanced prostate cancer and are receiving radiation therapy (Enrollment deadline: April 2019). Janssen Research & Development is seeking men to participate in a clinical trial of an investigatvional drug for prostate cancer. The selections will be random, and the investigational medication will be given to one out of every two study participants.

    To learn more about the ATLAS Study and to find out if you may be eligible, please visit: http://www.atlasprostatecancer.com/?p=3079USTOO1 or www.clinicaltrials.gov

    Study Identifier: NCT02531516
    Janssen Research & Development, LLC is part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

  • PCa003 Study - An investigational clinical study of Focal MR-Guided Focused Ultrasound Treatment of Localized Intermediate Risk Prostate Lesions; PCa003 is currently enrolling men with Gleason 7 prostate cancer.

    INSIGHTEC is seeking men with Gleason 7 prostate cancer to participate in a clinical trial of an investigational device for prostate lesions. The Focal MR-Guided Focused Ultrasound Treatment of Localized Intermediate Risk Prostate Lesions Study (PCa003) is a clinical trial currently enrolling men over 50 who have intermediate-risk, organ confined prostate cancer who have not had prior localized treatment for prostate cancer. All patients who qualify will undergo the investigational procedure and follow-up for 24 months post-treatment.

    To learn more about the PCa003 study and to find out if you may be eligible, please visit: https://www.insightec.com/clinical/urology or https://clinicaltrials.gov/ct2/show/NCT01657942?term=Exablate+prostate&rank=3

    Study Identifier: NCT01657942
    INSIGHTEC Ltd.

Locally advanced

  • The ATLAS Study - A clinical research study now enrolling for men who have high-risk, localized or locally advanced prostate cancer and are receiving radiation therapy (Enrollment deadline: April 2019)

    The ATLAS Study is a clinical research study now enrolling for men who have high-risk, localized or locally advanced prostate cancer and are receiving radiation therapy (Enrollment deadline: April 2019). Janssen Research & Development is seeking men to participate in a clinical trial of an investigatvional drug for prostate cancer. The selections will be random, and the investigational medication will be given to one out of every two study participants.

    To learn more about the ATLAS Study and to find out if you may be eligible, please visit: http://www.atlasprostatecancer.com/?p=3079USTOO1 or www.clinicaltrials.gov

    Study Identifier: NCT02531516
    Janssen Research & Development, LLC is part of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Rising PSA post-initial treatment

  • Phase II Trial of an Adenovirus/PSA Vaccine for Recurrent Prostate Cancer [012010]

    The University of Iowa and the Iowa City VA Medical Center are conducting a Phase II trial of a vaccine for the treatment of recurrent prostate cancer. Two protocols are active; one protocol treats hormone naïve patients who have experienced a recent, but continued rise in their serum PSA following initial treatment for their prostate cancer, and a second protocol treats men with hormone refractory prostate cancer. The hypothesis is that the vaccine will induce the production of anti-PSA and, therefore, anti-prostate cancer, immune responses that will cause the destruction of the cancer cells anywhere in the body.

    Interested patients can contact the Clinical Trial Coordinator Ms. Pamela Zehr at 319-353-8914, pamela-zehr@uiowa.edu or Dr. David Lubaroff at 319-335-8423, david-lubaroff@uowa.edu

    Click Here for clinicaltrials.gov listing with more information about this study

  • IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

    The purpose of this study is to show that abiraterone acetate plus prednisone added to the current standard of care, gonadotropin-releasing hormone (GnRH) decreases prostate specific antigen (PSA) and prolongs the time until it is evident that the cancer has grown. Additionally, safety information about abiraterone acetate in combination with prednisone will be collected. This will include looking at what side effects occur, how often they occur, and for how long they last.

    Inclusion Criteria:

    • Currently receiving and must have had continuous therapy with Gonadotropin-releasing hormone (GnRH) monotherapy for at least 6 months before screening, with a serum testosterone of < 50 nanograms/deciliter (< 2.0 nanograms per milliliter) or have undergone surgical removal of the testicles with a blood testosterone level of < 50 nanograms per deciliter (<2.0 nanograms per millimeter)

    • Have rising Prostate Specific Antigen (PSA) after local therapy and treatment with GnRH monotherapy (defined as a PSA of greater than or equal to 10 nanograms/milliliter obtained at screening or PSADT (prostate-specific antigen doubling time) of < or equal to 6 months with a baseline PSA of greater than or equal to 2.0 nanograms/milliliter)

    Exclusion Criteria:

    • Have prior or current evidence of local disease progression or metastatic disease as defined by modified response evaluation criteria in solid tumors (RECIST) criteria

    • Have received chemotherapy for treatment of castrate-resistant prostate cancer

    • Have a Prostate Specific Androgen Doubling Time (PSADT) of greater than 15 months

    http://www.clinicaltrials.gov/ct2/show/NCT01314118?term=prostate+cancer%2Cabiraterone&rank=19

Hormone refractory/hormone resistant

  • PROSPER clinical trial for patients with prostate cancer that has progressed on hormonal therapy but has not spread beyond the prostate.

    Click here to get more information and to register.

  • Phase II Trial of an Adenovirus/PSA Vaccine for Recurrent Prostate Cancer [012010]

    The University of Iowa and the Iowa City VA Medical Center are conducting a Phase II trial of a vaccine for the treatment of recurrent prostate cancer. Two protocols are active; one protocol treats hormone naïve patients who have experienced a recent, but continued rise in their serum PSA following initial treatment for their prostate cancer, and a second protocol treats men with hormone refractory prostate cancer. The hypothesis is that the vaccine will induce the production of anti-PSA and, therefore, anti-prostate cancer, immune responses that will cause the destruction of the cancer cells anywhere in the body.

    Interested patients can contact the Clinical Trial Coordinator Ms. Pamela Zehr at 319-353-8914, pamela-zehr@uiowa.edu or Dr. David Lubaroff at 319-335-8423, david-lubaroff@uowa.edu.

    Click Here for clinicaltrials.gov listing with more information about this study

  • Cancer Vaccine Trial: A Randomized Phase II Trial Combining Vaccine Therapy With PROSTVAC/TRICOM and Flutamide vs. Flutamide Alone in Men With Androgen Insensitive, Non-Metastatic (D0.5) Prostate Cancer

    Many men receiving hormonal therapy for prostate cancer develop a rising PSA but have no evidence of disease on bone scan or CT scan. Currently, there is no standard of care for these patients. In a prior clinical study, we showed preliminary clinical data that combining hormone therapy with a vaccine targeting PSA may benefit patients with this stage prostate cancer. In our current trial, patients will be randomized to receive either flutamide alone (an FDA-approved pill that is active in prostate cancer) or in combination with a prostate cancer vaccine to determine if the addition of the vaccine can improve the outcome (prolong disease progression) compared with flutamide alone. The study will also seek to understand the immunologic effects of these treatments.

    Dr. Ravi A. Madan, Principal Investigator

    Read here for Cancer Vaccine Trial details

Hormone refractory/hormone resistant AND Metastatic:

Metastatic

Multiple trials

  • Prostate cancer trials at the NIH Clinical Center in Bethesda, MD [080706]

    NCI currently conducting trials for patients with prostate cancer -- The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), conducts more than 150 clinical trials at the NIH Clinical Center in Bethesda, MD. NCI is currently conducting clinical trials for patients with prostate cancer.

    There is no charge for medical care received at the NIH Clinical Center. Study participants will be responsible for travel costs for their initial screening visits. Once participants are enrolled in a trial, NCI will pay for the transportation costs for all subsequent trial-related visits for participants who do not live in the local area. In addition, these participants will receive a small per diem for food and lodging expenses if they are being treated as outpatients.

    For more information on clinical trials conducted at NCI, please visit http://bethesdatrials.cancer.gov or call the Clinical Trials Referral Office (formerly Clinical Studies Support Center) at 1-888-NCI-1937 (1-888-624-1937). 

    The National Cancer Institute also sponsors clinical studies at cancer centers nationwide. To learn more about these studies, call 1-800-4-CANCER (1-800-422-6237).

CLICK HERE and opt-in to receive free educational emails from Us TOO.